{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:22:53Z","timestamp":1790677373119,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T00:00:00Z","timestamp":1414108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s11136-014-0833-2","type":"journal-article","created":{"date-parts":[[2014,10,23]],"date-time":"2014-10-23T16:15:36Z","timestamp":1414080936000},"page":"837-844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of EQ-5D and SF-6D utilities in Pompe disease"],"prefix":"10.1007","volume":"24","author":[{"given":"T. A.","family":"Kanters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. K.","family":"Redekop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Kruijshaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P. M. H.","family":"Rutten-van M\u00f6lken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hakkaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,24]]},"reference":[{"key":"833_CR1","unstructured":"European Commission. (2000). Regulation (EC) no 141\/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities, L18\/1."},{"key":"833_CR2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJMp058317","volume":"354","author":"ME Haffner","year":"2006","unstructured":"Haffner, M. E. (2006). Adopting orphan drugs\u2014two dozen years of treating rare diseases. New England Journal of Medicine, 354, 445\u2013447.","journal-title":"New England Journal of Medicine"},{"key":"833_CR3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1750-1172-6-62","volume":"6","author":"C Schey","year":"2011","unstructured":"Schey, C., Milanova, T., & Hutchings, A. (2011). Estimating the budget impact of orphan medicines in Europe: 2010\u20132020. Orphanet Journal of Rare Diseases, 6, 62.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"833_CR4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1017\/S0266462307051550","volume":"23","author":"MF Drummond","year":"2007","unstructured":"Drummond, M. F., Wilson, D. A., Kanavos, P., Ubel, P., & Rovira, J. (2007). Assessing the economic challenges posed by orphan drugs. International Journal of Technology Assessment in Health Care, 23, 36\u201342.","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"833_CR5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT Ploeg Van der","year":"2008","unstructured":"van der Ploeg, A. T., & Reuser, A. J. J. (2008). Pompe\u2019s disease. The Lancet, 372, 1342\u20131353.","journal-title":"The Lancet"},{"key":"833_CR6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","volume":"7","author":"MGEM Ausems","year":"1999","unstructured":"Ausems, M. G. E. M., Verbiest, J., Hermans, M. M. P., Kroos, M. A., Beemer, F. A., Wokke, J. H. J., et al. (1999). Frequency of glycogen storage disease type II in the Netherlands: Implications for diagnosis and genetic counselling. European Journal of Human Genetics, 7, 713\u2013716.","journal-title":"European Journal of Human Genetics"},{"key":"833_CR7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2011.06.012","volume":"104","author":"NAME Beek Van der","year":"2011","unstructured":"Van der Beek, N. A. M. E., Van Capelle, C. I., Van der Velden-Van Etten, K. I., Hop, W. C. J., Van den Berg, B., Reuser, A. J. J., et al. (2011). Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Molecular Genetics and Metabolism, 104, 129\u2013136.","journal-title":"Molecular Genetics and Metabolism"},{"key":"833_CR8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","volume":"17","author":"W M\u00fcller-Felber","year":"2007","unstructured":"M\u00fcller-Felber, W., Horvath, R., Gempel, K., Podskarbi, T., Shin, Y., Pongratz, D., et al. (2007). Late onset Pompe disease: Clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscular Disorders, 17, 698\u2013706.","journal-title":"Neuromuscular Disorders"},{"key":"833_CR9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-7-88","volume":"7","author":"NAME Beek Van der","year":"2012","unstructured":"Van der Beek, N. A. M. E., De Vries, J. M., Hagemans, M. L., Hop, W. C., Kroos, M. A., Wokke, J. H., et al. (2012). Clinical features and predictors for disease natural progression in adults with Pompe disease: A nationwide prospective observational study. Orphanet Journal of Rare Diseases, 7, 88.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"833_CR10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nmd.2008.11.007","volume":"19","author":"NAME Beek Van der","year":"2009","unstructured":"Van der Beek, N. A. M. E., Hagemans, M. L. C., Reuser, A. J. J., Hop, W. C. J., van der Ploeg, A. T., Van Doorn, P. A., et al. (2009). Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscular Disorders, 19, 113\u2013117.","journal-title":"Neuromuscular Disorders"},{"key":"833_CR11","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.WNL.0000142597.69707.78","volume":"63","author":"MLC Hagemans","year":"2004","unstructured":"Hagemans, M. L. C., Janssens, A., Winkel, L. P. F., Sieradzan, K. A., Reuser, A. J. J., Van Doorn, P. A., et al. (2004). Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology, 63, 1688\u20131692.","journal-title":"Neurology"},{"key":"833_CR12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10545-011-9320-x","volume":"34","author":"TA Kanters","year":"2011","unstructured":"Kanters, T. A., Hagemans, M. L. C., Van der Beek, N. A. M. E., Rutten, F. F. H., van der Ploeg, A. T., & Hakkaart, L. (2011). Burden of illness of Pompe disease in patients only receiving supportive care. Journal of Inherited Metabolic Disease, 34, 1045\u20131052.","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"833_CR13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","volume":"6","author":"D G\u00fcng\u00f6r","year":"2011","unstructured":"G\u00fcng\u00f6r, D., De Vries, J. M., Hop, W. C. J., Reuser, A. J. J., Van Doorn, P. A., van der Ploeg, A. T., et al. (2011). Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet Journal of Rare Diseases, 6, 34.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"833_CR14","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/hec.1125","volume":"15","author":"LM Lamers","year":"2006","unstructured":"Lamers, L. M., Bouwmans, C. A. M., Van Straten, A., Donker, M. C. H., & Hakkaart, L. (2006). Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Economics, 15, 1229\u20131236.","journal-title":"Health Economics"},{"key":"833_CR15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1524-4733.2009.00669.x","volume":"13","author":"M Joore","year":"2010","unstructured":"Joore, M., Brunenberg, D., Nelemans, P., Wouters, E., Kuijpers, P., Honig, A., et al. (2010). The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: Results across five trial-based cost-utility studies. Value in Health, 13, 222\u2013229.","journal-title":"Value in Health"},{"key":"833_CR16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/MLR.0b013e3181a39428","volume":"47","author":"TH Sach","year":"2009","unstructured":"Sach, T. H., Barton, G. R., Jenkinson, C., Doherty, M., Avery, A. J., & Muir, K. R. (2009). Comparing cost-utility estimates: Does the choice of EQ-5D or SF-6D matter? Medical Care, 47, 889\u2013894.","journal-title":"Medical Care"},{"key":"833_CR17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks, R. (1996). EuroQol: The current state of play. Health Policy, 37, 53\u201372.","journal-title":"Health Policy"},{"key":"833_CR18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","volume":"21","author":"J Brazier","year":"2002","unstructured":"Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21, 271\u2013292.","journal-title":"Journal of Health Economics"},{"key":"833_CR19","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35, 1095\u20131108.","journal-title":"Medical Care"},{"key":"833_CR20","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hec.866","volume":"13","author":"J Brazier","year":"2004","unstructured":"Brazier, J., Tsuchiya, A., Roberts, J., & Busschbach, J. (2004). A comparison of the EQ-5D and the SF-6D across seven patient groups. Health Economics, 13, 873\u2013884.","journal-title":"Health Economics"},{"key":"833_CR21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s11136-004-3211-7","volume":"14","author":"K Stavem","year":"2005","unstructured":"Stavem, K., Fr\u00f8land, S. S., & Hellum, K. B. (2005). Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV\/AIDS. Quality of Life Research, 14, 971\u2013980.","journal-title":"Quality of Life Research"},{"key":"833_CR22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11136-008-9429-z","volume":"18","author":"A Szende","year":"2009","unstructured":"Szende, A., Leidy, N. K., St\u00e5hl, E., & Svensson, K. (2009). Estimating health utilities in patients with asthma and COPD: Evidence on the performance of EQ-5D and SF-6D. Quality of Life Research, 18, 267\u2013272.","journal-title":"Quality of Life Research"},{"key":"833_CR23","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.socscimed.2004.08.034","volume":"60","author":"CA Marra","year":"2005","unstructured":"Marra, C. A., Woolcott, J. C., Kopec, J. A., Shojania, K., Offer, R., Brazier, J. E., et al. (2005). A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Social Science and Medicine, 60, 1571\u20131582.","journal-title":"Social Science and Medicine"},{"key":"833_CR24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/jnnp.2003.017897","volume":"76","author":"JD Fisk","year":"2005","unstructured":"Fisk, J. D., Brown, M. G., Sketris, I. S., Metz, L. M., Murray, T. J., & Stadnyk, K. J. (2005). A comparison of health utility measures for the evaluation of multiple sclerosis treatments. Journal of Neurology, Neurosurgery and Psychiatry, 76, 58\u201363.","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"833_CR25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","volume":"16","author":"PH Quanjer","year":"1993","unstructured":"Quanjer, P. H., Tammeling, G. J., Cotes, J. E., Pedersen, O. F., Peslin, R., & Yernault, J. C. (1993). Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. official statement of the European respiratory society. European Respiratory Journal. Supplement, 16, 5\u201340.","journal-title":"European Respiratory Journal. Supplement"},{"key":"833_CR26","volume-title":"Aids to the examination of the peripheral nervous system","author":"Medical Research Council","year":"1986","unstructured":"Medical Research Council. (1986). Aids to the examination of the peripheral nervous system. London: Tindall."},{"key":"833_CR27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1750-1172-7-73","volume":"7","author":"JM Vries De","year":"2012","unstructured":"De Vries, J. M., Van der Beek, N. A. M. E., Hop, W. C. J., Karstens, F. P. J., Wokke, J. H., De Visser, M., et al. (2012). Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: An open-label single-center study. Orphanet Journal of Rare Diseases, 7, 73.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"833_CR28","volume-title":"Discovering statistics using SPSS","author":"AP Field","year":"2009","unstructured":"Field, A. P. (2009). Discovering statistics using SPSS. London: SAGE publications Ltd."},{"key":"833_CR29","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780199231881.001.0001","volume-title":"Health measurement scales","author":"DL Streiner","year":"2008","unstructured":"Streiner, D. L., & Norman, G. R. (2008). Health measurement scales. Oxford: Oxford University Press."},{"key":"833_CR30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10198-002-0105-x","volume":"3","author":"S Ghislandi","year":"2002","unstructured":"Ghislandi, S., Apolone, G., Garattini, L., & Ghislandi, I. (2002). Is EQ-5D a valid measure of HRQoL in patients with movement disorders? The European Journal of Health Economics, 3, 125\u2013130.","journal-title":"The European Journal of Health Economics"},{"key":"833_CR31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1524-4733.2007.00230.x","volume":"11","author":"MF Janssen","year":"2008","unstructured":"Janssen, M. F., Birnie, E., Haagsma, J. A., & Bonsel, G. J. (2008). Comparing the standard EQ-5D three-level system with a five-level version. Value in Health, 11, 275\u2013284.","journal-title":"Value in Health"},{"key":"833_CR32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-008-9309-6","volume":"17","author":"HM McTaggart-Cowan","year":"2008","unstructured":"McTaggart-Cowan, H. M., Marra, C. A., Yang, Y., Brazier, J. E., Kopec, J. A., FitzGerald, J. M., et al. (2008). The validity of generic and condition-specific preference-based instruments: The ability to discriminate asthma control status. Quality of Life Research, 17, 453\u2013462.","journal-title":"Quality of Life Research"},{"key":"833_CR33","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s11136-007-9207-3","volume":"16","author":"D Khanna","year":"2007","unstructured":"Khanna, D., Furst, D. E., Wong, W. K., Tsevat, J., Clements, P. J., Park, G. S., et al. (2007). Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Quality of Life Research, 16, 1083\u20131092.","journal-title":"Quality of Life Research"},{"key":"833_CR34","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hec.1124","volume":"15","author":"LM Lamers","year":"2006","unstructured":"Lamers, L. M., McDonnell, J., Stalmeier, P. F. M., Krabbe, P. F. M., & Busschbach, J. J. V. (2006). The Dutch tariff: Results and arguments for an effective design for national EQ-5D valuation studies. Health Economics, 15, 1121\u20131132.","journal-title":"Health Economics"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-014-0833-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11136-014-0833-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-014-0833-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:00:48Z","timestamp":1559361648000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11136-014-0833-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,24]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["833"],"URL":"https:\/\/doi.org\/10.1007\/s11136-014-0833-2","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,24]]}}}